Topic summary

Retatrutide mass and identity: what a report should show

Compounds › Retatrutide TRIUMPH programme preprint retatrutide effect size Solved

This is a generated summary. It shows the 5 most-liked posts from a topic of 28, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

n.torrenceTL3Regular18 Jun 2026#1

Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that.

The question about retatrutide mass and identity that I actually want answered is the second one below. The first is context and I have kept it short.

Both are stated with units, and I have said what I already checked so that nobody repeats it.

21 likes 1mo

t.karlsenTL221 Jun 2026#2

On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and a chromatographic result together say considerably more than either alone.

Reporting the observation and leaving the explanation open deliberately.

24 likes 1mo

cannula_notesTL2Member Solution30 Jun 2026#7

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

I have no interest in any supplier named above.

7 likes 28d

p.mwangiTL29 Jul 2026#13

n.ekstrom, post #3: Practical experience of retatrutide mass and identity, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable. Go to post

Coming back to post #10, because the follow-up matters more than the original answer.

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

28 likes in reply to #3 19d

f.weissTL214 Jul 2026#17

t.karlsen, post #2: On identity confirmation more generally: for a compound with no widely available reference material, orthogonal confirmation matters more than usual. A mass result and a chromatographic result together say considerably more than either alone. Reporting the observation and leaving the explanation open deliberately. Go to post

I read post #13 twice before replying, because I had assumed the opposite.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

That is what the documentation says. What happens in practice is usually close.

20 likes in reply to #2 14d

Read the full topic (28 posts)

Suggested topics

Topic	Participants	Replies	Views	Activity
Second pass at: Retatrutide dose escalation in the published trials Compounds › Retatrutide retatrutide randomised trial preprint Under review Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…	+115	125	30k	2y
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper Compounds › Retatrutide retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. A follow-up question about Retatrutide phase 2 in type that I did…	+1	5	31k	8mo
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Compounds › Retatrutide effect size randomised trial TRIUMPH programme Solved Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post,…		2	103	17mo
Second pass at: Retatrutide mass and identity: what a report should show Compounds › Retatrutide retatrutide randomised trial effect size Solved Second pass at: Retatrutide mass and identity: what a report should show — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on…	+65	71	4.6k	13mo
[2026 update] What we do not know about retatrutide, listed explicitly Compounds › Retatrutide TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question…	+79	83	952	11mo

Related topics — sharing the tags TRIUMPH programme, preprint, retatrutide

Topic	Participants	Replies	Views	Activity
What would change my mind about repair peptides: a specific answer — one year on Compounds › Repair & healing peptides needs a source observational data TB-500 preprint Closed What would change my mind about repair peptides: a specific answer — one year on I have a specific reason for asking rather than idle curiosity, and the context is below. Documentation question rather than a…	+9	13	42k	19mo
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? Compounds › Repair & healing peptides needs a source preprint BPC-157 Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. The question about Analytical…	+28	33	1.6k	1mo
Journal club: SELECT, absolute risk, and how it was reported Evidence › Journal club journal club estimand randomised trial effect size Journal club: SELECT, absolute risk, and how it was reported Writing it up because I had to work it out twice and would rather nobody else did. A question about what the numbers mean rather than what they…		2	52k	1mo
What pooling buys you and what it destroys Evidence › Meta-analyses publication bias risk of bias meta-analysis heterogeneity Solved The question in the title: What pooling buys you and what it destroys I will give what I have already checked below so nobody repeats it. The question about pooling buys that I actually want answered is the…	+74	83	6.6k	8mo
A well-designed study with a badly written abstract Evidence › Study critique disputed effect size risk of bias observational data Posting this under the heading it deserves: A well-designed study with a badly written abstract Everything below is what sits behind that. Reading back through what has been written here about well-designed…	+117	128	7.2k	14mo